Le Lézard

News by subject: TRI

1 2 3 4 5 6 7 8 9 10

Today

12:30
The "Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis" report has been added to ResearchAndMarkets.com's offering. This...

12:00
FB2001 (Bofutrelvir) is a Coronavirus Mpro inhibitor, which exhibited potent anti-SARS-CoV-2 activity in vitro and in vivoPhase 1 results show FB2001 to be generally safe and well tolerated. No significant difference was observed between Chinese and...

11:03
Ondine Biomedical Inc. (LON: OBI), has recruited the final patient to its nasal photodisinfection exploratory Phase 2 trial. The trial is evaluating how effectively Ondine's nasal photodisinfection technology eradicates pathogens ? specifically...

11:00
A large international study of patients with non-small cell lung cancer tumors that are two centimeters or less found that sub lobar surgery was non-inferior to lobectomy, according to...

09:38
NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announces the appointment of new members of its Scientific Advisory Board. Dr. Keith Watson (Owner & Managing Director, KRW BioReg...

09:07
Beacon Biosignals, a startup that applies AI to EEG to unlock precision medicine for neurological and psychiatric disorders, presented research at the Alzheimer's Association International Conference, which took place July 31?Aug. 4, 2022, in San...

09:05
Pulmatrix, Inc. , a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSEtm technology, today announced second quarter financial results for 2022 and provided a...

09:00
Signant Health, the leader in evidence generation for modern clinical trials, announced a partnership with Loftware to offer customers integrated clinical trial supply labeling and packaging capabilities. Loftware is the leading provider of labeling...

08:00
Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of novel...

08:00
VolitionRx Limited ("Volition"), a multi-national epigenetics company, has appointed Diagnostic Oncology CRO, LLC ("DXOCRO") to undertake development and clinical validation studies for its Nu.Q® product portfolio in the United States. DXOCRO will...

08:00
An interim analysis of overall survival data from the...

07:55
Calyx, the eClinical and Regulatory solutions and services provider relied on for solving complex data challenges in clinical research, today announced it has achieved a milestone in supporting the clinical development of approved treatments for rare...

07:00
Compugen Ltd. , a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the European Patent Office has granted Compugen a new patent covering anti-PVRIG antibodies for use in cancer...

07:00
As has been demonstrated by many studies, contoured prism has historically shown efficacy in relieving symptoms as a therapeutic offering. And new evidence suggests that there is also an opportunity to expand this technology to an even broader...

06:30
Tarcocimab tedromer (KSI-301) dosed every two months met the primary endpoint of non-inferior visual acuity gains compared to aflibercept dosed every monthFirst anti-VEGF therapy to achieve non-inferiority in visual acuity gains while doubling the...

04:30
Patients with lung cancer who attended a lung cancer screening event and who then participated in a personalized smoking cessation study achieved smoking...


7 august 2022

20:10
--ASC61 is an in-house developed oral PD-L1 small molecule inhibitor prodrug that showed significant antitumor efficacy in preclinical studies as a single agent in multiple animal models --ASC61-A treatment induced secretion of IFN? in a...

20:05
GEMSTONE-301 study result was presented at IASLC 2022 World Conference on Lung Cancer. In addition, the leading Principal Investigator Professor Yi-Long Wu was invited to highlight key data in a press conferenceIn the final progression-free survival...

20:00
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major...

04:10
Amgen  today announced three new data sets from its thoracic oncology portfolio that will be presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World...

04:10
The protocol used to screen and detect lung cancer in the NELSON Trial is more sensitive than the protocol used in the National Lung Cancer Screening Trial,...


5 august 2022

16:30
Kodiak Sciences Inc. , a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has completed enrollment in its GLOW Phase 3...

08:45
United BioPharma (UBP) today announced their latest results featuring unprecedented and unique functional characteristics of UB-221 monoclonal antibody in the phase I single-dose clinical trial, with chronic spontaneous urticaria (CSU) patients, to...

08:43
We are increasingly being exposed to endocrine-disrupting chemicals (EDCs) that interfere with the normal functioning of our hormones. Bisphenol A (BPA) and phthalates, which are widely used in consumer products including plastics, aluminum cans,...

08:40
Kazia Therapeutics Limited , an oncology-focused drug development company, is pleased to announce the presentation of promising new data from an ongoing phase I clinical trial of paxalisib in combination with radiotherapy for the treatment of brain...

08:30
Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced the...

06:30
Nuvalent, Inc. , a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced new preclinical data supporting the potential best-in-class profile of...

00:07
Dizal presented positive clinical updates highlighting the therapeutic potential of sunvozertinib in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor exon 20 insertion (EGFR Exon20ins) mutation at 2022 World Conference on Lung...


4 august 2022

16:05
DURECT Corporation today announced financial results for the three months ended June 30, 2022 and provided a corporate update. "We continue to see enrollment accelerating in the larsucosterol (DUR-928) AHFIRM trial and are pleased to announce that...

16:02
Akebia Therapeutics®, Inc. , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced initial findings from an investigator-sponsored study evaluating vadadustat, Akebia's investigational...

14:02
Results of a study just published in Frontiers in Digital Health, an international scientific journal, show that teen drug use can be cut dramatically using a newly developed e-learning program that is fun, engaging, and easily accessed with digital...

12:33
In a groundbreaking 13-year study, Pacific Neuroscience Institute neurosurgical and otolaryngology surgical teams demonstrated outstanding outcomes with minimally invasive keyhole surgery for the most common primary brain tumor, in the largest such...

11:15
The "Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2015 - 2022" report has been added to ResearchAndMarkets.com's offering. The report provides a detailed understanding and analysis of how, why and on what terms...

09:03
Novavax, Inc. , a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the initiation of its Phase 2b/3 Hummingbirdtm global clinical trial. The trial will...

08:56
Berkeley Lights, Inc. , a leader in digital cell biology, and the Jaime Leandro Foundation for Therapeutic Cancer Vaccines (JLF), today announced the discovery, functional characterization, and recovery of a patient-derived T cell receptor sequence...

08:00
Today, the Bladder Cancer Advocacy Network, (BCAN), announced its first-ever Translational Clinical Trial Award (TCTA) to support patient-oriented research to transform bladder cancer care. The award will provide a maximum of $3 million in funding...

07:00
Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has selected the GenomOncology Precision Oncology Platform for the development of a novel ground-breaking CE-IVD Precision Oncology...

07:00
FDA Clearance of IND Application for OTX-2002, the First Ever Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma ReceivedLaunch of Phase 1/2 Clinical Trial Under the MYCHELANGELOTM Clinical Program in Patients Expected in 2H'22 Data from...

02:15
ADESOS is a Phase 2b dose-finding study of orismilast modified release (MR) tablet in moderate to severe atopic dermatitis (AD) with the purpose of identifying the appropriate dose-regimen for Phase 3 studiesAD is the most common chronic inflammatory...


3 august 2022

19:32
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced that Eisai presented new findings on a subcutaneous formulation of lecanemab (BAN2401) and the modeling simulation of the impact of ApoE4 genotype on the...

16:05
RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, remains on track for first BLA filing in 2024 Enrollment ongoing in the pivotal ATMOSPHERE® and ASCENTtm clinical trials of RGX-314...

16:00
Vial is welcoming Dr. Luke Nordquist to Vial's Oncology Scientific Advisory Board. Dr. Nordquist is the latest addition to the board after Dr. Arati Rao, Dr. Antoni Ribas, Dr. Arvind Chaudhry, and Dr. Guru Sonpavde joined earlier this year....

13:49
PhorMed Inc, a Nevada Corporation ("PhorMed" or the "Company"), is a privately held clinical stage biopharmaceutical company. The Company's study drug RP-323 is in an on-going acute respiratory distress syndrome (ARDS) study. ARDS is a lung disorder...

10:23
Jubilant Therapeutics Inc., a biopharmaceutical Company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced U.S. Food and Drug Administration (US FDA) clearance of the...

09:05
Butterfly Medical, an Israeli medical device company developing a novel minimally invasive solution to treat Benign Prostatic Hyperplasia (BPH), today announced its first procedures performed in-office under local anesthesia in its clinical study in...

08:52
Over 45,900 people died from suicide in 2020. To help health-care providers reduce the number of suicides, SIMmersion created training systems featuring realistic virtual role-players who are at risk.  Introduction: Suicide is often preventable. One...

08:46
A new study on the effectiveness of plant-based organs for use in surgical training was performed by Dr. Naoki Nishio at the Nagoya University Graduate School of Medicine. The study was published in the Laryngoscope Investigative Otolaryngology...

08:42
When the body's immune system turns on itself and attacks the body's healthy cells and organs, we develop autoimmune disorders. A rare entrant in the list of autoimmune disorders is acquired hemophilia A (AHA) in which spontaneous bleeding occurs in...

08:39
There is no therapeutic that has been shown to stop or reverse the devastating memory loss of Alzheimer's Disease. That may have all changed today with publication of a scientific paper in the journal Medicines. The paper reports that a small group...

08:30
- Commentary points to need for a vaccine based on nucleocapsid vs. spike protein to make vaccine less vulnerable to mutation and provide stronger immunity to novel viral variants - Company's development of a nucleocapsid vaccine, a recombinant...

1 2 3 4 5 6 7 8 9 10